Acceptability of on-site rapid HIV/HBV/HCV testing and HBV vaccination among three at-risk populations in distinct community-healthcare outreach centres: the ANRS-SHS 154 CUBE study.
Adolescent
Adult
Community Health Services
Female
HIV Infections
/ diagnosis
HIV-1
/ immunology
HIV-2
/ immunology
Hepacivirus
/ immunology
Hepatitis B virus
/ immunology
Hepatitis B, Chronic
/ diagnosis
Hepatitis C, Chronic
/ diagnosis
Homosexuality, Male
Humans
Longitudinal Studies
Male
Mass Screening
/ methods
Paris
/ epidemiology
Pilot Projects
Prospective Studies
Risk Factors
Serologic Tests
Sex Workers
Sexual and Gender Minorities
Substance Abuse, Intravenous
Transgender Persons
Vaccination
Viral Vaccines
/ immunology
Young Adult
Community sites
HBV testing
HBV vaccination
HCV
Linkage-to-care
On-site rapid HIV testing
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
16 Nov 2020
16 Nov 2020
Historique:
received:
28
01
2020
accepted:
09
11
2020
entrez:
17
11
2020
pubmed:
18
11
2020
medline:
15
12
2020
Statut:
epublish
Résumé
HIV, HBV and HCV infections continue to represent major health concerns, especially among key at-risk populations such as men who have sex with men (MSM), people who inject drugs (PWIDs), transgender women (TGW) and sex workers (SW). The objective of the ANRS-CUBE study was to evaluate the acceptability of a healthcare, community-based strategy offering a triple rapid HIV-HBV-HCV testing, and HBV vaccination, targeted at three priority groups (MSM, PWIDs and TGW/SWs), in three community centers, in the Paris area. This longitudinal multicentric non-randomized study included all adult volunteers attending one of the three specialized community centers in Paris, between July 2014 and December 2015. HIV, HBV and HCV status and acceptability of HBV vaccination were evaluated. A total of 3662, MSM, 80 PWIDs and 72 TGW/SW were recruited in the three centers respectively. Acceptability of rapid tests was 98.5% in MSM and 14.9% in TGW/SWs, but could not be estimated in PWIDs since the number of users attending and the number of proposals were not recorded. User acceptability of HBV vaccination was weak, only 17.9% of the eligible MSM (neither vaccinated, nor infected) agreed to receive the first dose, 12.2% two doses, 5.9% had a complete vaccination. User acceptability of HBV vaccination was greater in PWIDs and TGW/SWs, but decreased for the last doses (66.7 and 53.3% respectively received a first dose, 24.4 and 26.7% a second dose and 6.7 and 0% a third dose). Fifty-three participants (49 MSM and 4 PWIDs) were discovered HIV positive, more than half with a recent infection. All but two HIV positive participants were linked to appropriate care in less than one month. Rapid HIV-HCV-HBV screening showed a very high level of acceptability among MSM. Efforts need to be made to improve immediate acceptability for HBV vaccination, especially among MSM, and follow-up doses compliance. Our results show the important role of community centers in reaching targets, often fragile, populations, while also suggesting the need to reinforce on-site human support in terms of testing and vaccination, especially when addressing PWIDs.
Sections du résumé
BACKGROUND
BACKGROUND
HIV, HBV and HCV infections continue to represent major health concerns, especially among key at-risk populations such as men who have sex with men (MSM), people who inject drugs (PWIDs), transgender women (TGW) and sex workers (SW). The objective of the ANRS-CUBE study was to evaluate the acceptability of a healthcare, community-based strategy offering a triple rapid HIV-HBV-HCV testing, and HBV vaccination, targeted at three priority groups (MSM, PWIDs and TGW/SWs), in three community centers, in the Paris area.
METHODS
METHODS
This longitudinal multicentric non-randomized study included all adult volunteers attending one of the three specialized community centers in Paris, between July 2014 and December 2015. HIV, HBV and HCV status and acceptability of HBV vaccination were evaluated.
RESULTS
RESULTS
A total of 3662, MSM, 80 PWIDs and 72 TGW/SW were recruited in the three centers respectively. Acceptability of rapid tests was 98.5% in MSM and 14.9% in TGW/SWs, but could not be estimated in PWIDs since the number of users attending and the number of proposals were not recorded. User acceptability of HBV vaccination was weak, only 17.9% of the eligible MSM (neither vaccinated, nor infected) agreed to receive the first dose, 12.2% two doses, 5.9% had a complete vaccination. User acceptability of HBV vaccination was greater in PWIDs and TGW/SWs, but decreased for the last doses (66.7 and 53.3% respectively received a first dose, 24.4 and 26.7% a second dose and 6.7 and 0% a third dose). Fifty-three participants (49 MSM and 4 PWIDs) were discovered HIV positive, more than half with a recent infection. All but two HIV positive participants were linked to appropriate care in less than one month.
CONCLUSIONS
CONCLUSIONS
Rapid HIV-HCV-HBV screening showed a very high level of acceptability among MSM. Efforts need to be made to improve immediate acceptability for HBV vaccination, especially among MSM, and follow-up doses compliance. Our results show the important role of community centers in reaching targets, often fragile, populations, while also suggesting the need to reinforce on-site human support in terms of testing and vaccination, especially when addressing PWIDs.
Identifiants
pubmed: 33198672
doi: 10.1186/s12879-020-05601-7
pii: 10.1186/s12879-020-05601-7
pmc: PMC7670674
doi:
Substances chimiques
Viral Vaccines
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
851Références
Front Public Health. 2018 Aug 14;6:192
pubmed: 30155454
J Int AIDS Soc. 2016 Jul 17;19(3 Suppl 2):20799
pubmed: 27431470
Am J Public Health. 2012 Jun;102(6):1160-7
pubmed: 22515871
Int J Drug Policy. 2015 Nov;26(11):1050-5
pubmed: 26118799
Lancet. 2014 Jul 12;384(9938):153-63
pubmed: 24725468
Rev Epidemiol Sante Publique. 2016 Sep;64(4):301-12
pubmed: 26904917
J Int AIDS Soc. 2018 Mar;21(3):e25100
pubmed: 29603879
BMC Infect Dis. 2019 Apr 11;19(1):315
pubmed: 30971207
Lancet Infect Dis. 2013 Mar;13(3):214-22
pubmed: 23260128
Epidemiol Infect. 2017 Apr;145(5):895-907
pubmed: 28004616
Sex Transm Infect. 2006 Dec;82(6):458-60
pubmed: 16923739
BMJ Open. 2014 Dec 15;4(12):e005040
pubmed: 25510882
Open Forum Infect Dis. 2016 Apr 06;3(2):ofw075
pubmed: 27191007
BMJ Open. 2012 Apr 01;2(2):e000693
pubmed: 22466158
AIDS. 2016 Jul 17;30(11):1857-8
pubmed: 27351929
J Infect Dis. 2010 Oct 15;202 Suppl 2:S270-7
pubmed: 20846033
Addiction. 2013 Jun;108(6):1070-81
pubmed: 23347124
BMC Public Health. 2014 Jun 25;14:645
pubmed: 24965699
Clin Infect Dis. 2012 Nov 15;55(10):1408-16
pubmed: 22893583
Public Health Rep. 1993 Jan-Feb;108(1):12-8
pubmed: 8434087
Infection. 2017 Jun;45(3):309-321
pubmed: 28005195
Am J Public Health. 2015 Jun;105(6):e36-43
pubmed: 25880946
J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25050
pubmed: 29633520
Prev Med. 2013 Oct;57(4):297-303
pubmed: 23639625
J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):511-8
pubmed: 15021316
Epidemiol Infect. 2017 Jan 19;:1-11
pubmed: 28100289
BMC Infect Dis. 2009 Jul 16;9:113
pubmed: 19607712
J Community Health. 2014 Oct;39(5):922-34
pubmed: 25135842
Open Forum Infect Dis. 2015 Oct 26;2(4):ofv162
pubmed: 26668814
PLoS One. 2020 Jan 15;15(1):e0227576
pubmed: 31940331
BMC Public Health. 2014 Aug 09;14:820
pubmed: 25107530
PLoS One. 2012;7(2):e30609
pubmed: 22363453
Liver Int. 2016 Oct;36(10):1442-9
pubmed: 27043826
PLoS One. 2013 Apr 16;8(4):e61225
pubmed: 23613817
BMJ Glob Health. 2017 Mar 7;2(2):e000227
pubmed: 28589026